<DOC>
	<DOCNO>NCT00369551</DOCNO>
	<brief_summary>This phase I trial study well give bevacizumab together paclitaxel , carboplatin , radiation therapy chest work treat patient locally advance non-small cell lung cancer . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Drugs use chemotherapy , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving bevacizumab together paclitaxel , carboplatin , radiation therapy may kill tumor cell .</brief_summary>
	<brief_title>Bevacizumab , Paclitaxel , Carboplatin , Radiation Therapy Chest Treating Patients With Locally Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Assess feasibility administer bevacizumab , paclitaxel , carboplatin , chest radiotherapy patient locally advance non-small cell lung cancer . II . Characterize toxicity treatment regimen . III . Assess clinical response treatment regimen . IV . Correlate circulating level angiopoietin-2 vascular endothelial growth factor receptor-2 clinical response treatment regimen . OUTLINE : This open-label , multicenter study.Induction therapy . Patients receive paclitaxel IV 1 hour carboplatin IV 30-60 minute day 1 , 8 , 15 , 22 , 29 , 36 , 43 bevacizumab IV 30-90 minute day 1 , 15 , 29 , 43 . Patients also undergo chest radiotherapy 5 day week 7 week begin day 1 . Consolidation therapy : Beginning 4-5 week completion chemoradiotherapy , patient receive paclitaxel IV 1 hour follow carboplatin IV 1 hour follow bevacizumab IV 30 minute . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . After study completion , patient follow periodically 36 month . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Adenocarcinoma , Bronchiolo-Alveolar</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm nonsmall cell lung carcinoma ( NSCLC ) meeting follow criterion : The follow subtypes eligible : Adenocarcinoma ( include bronchoalveolar ) Large cell carcinoma ( include giant clear cell carcinoma ) Poorly differentiate carcinoma No squamous cell histology Unresectable stage IIIII disease Tumor must invade trachea major arterial venous structure Measurable evaluable disease Measurable disease define ? 1 lesion accurately measure ? 1 dimension ? 20 mm conventional technique ? 10 mm spiral CT scan No evidence CNS disease , include primary brain tumor brain metastasis ECOG performance status ( PS ) 01 Karnofsky PS 60100 % Life expectancy &gt; 6 month Granulocyte count ? 1,500/mm³ Platelet count ? 100,000/mm³ Bilirubin &lt; 1.25 time upper limit normal ( ULN ) AST &lt; 2.5 time ULN Creatinine normalOR creatinine clearance ? 60 mL/min FEV_1 ? 1.0 liter 24hour urine protein &lt; 1,000 mg ( patient urine protein : creatinine ratio [ urine analysis ] &gt; 1.0 ) No hemoptysis within past 12 month ( define bright red blood sputum &gt; 1 teaspoon ) No know hypersensitivity Chinese hamster ovary cell product recombinant human antibodies No history allergic reaction attribute carboplatin taxane No serious nonhealing wound , ulcer , bone fracture No abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 28 day No significant traumatic injury within past 14 day No clinically significant cardiovascular disease , include follow : Cerebrovascular accident within past 6 month Uncontrolled hypertension Myocardial infarction unstable angina within past 6 month New York Heart Association class IIIV congestive heart failure Serious cardiac arrhythmia require medication Unstable angina pectoris Clinically significant peripheral vascular disease No known bleed diathesis coagulopathy No active bleed pathological condition carry high risk bleeding ( e.g. , tumor involve major vessel know varix ) No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Psychiatric illness social situation would limit study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ? 6 month completion study treatment No HIV positivity No prior chemotherapy No prior epidermal growth factor receptortargeted therapy No prior vascular endothelial growth factortargeted therapy No prior chest radiotherapy No major surgery open biopsy within past 14 day No concurrent treatment fulldose anticoagulation Lowdose anticoagulant ( e.g. , warfarin ) maintain patency central venous catheter allow provide follow criterion meet : Daily dose warfarin &lt; 1 mg INR &lt; 1.5 No concurrent investigational agent No concurrent major surgical procedure No concurrent anticancer agent therapies No concurrent chronic treatment aspirin ( &gt; 325 mg daily ) nonsteroidal antiinflammatory agent No dexamethasone antiemetic chemoradiotherapy No colonystimulating factor chemoradiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>